Key result
Pulmonary vasodilators may mitigate long-term sequelae in patients with failing Fontan circulation.
Why the study?
The long-term consequences and limitations of Fontan physiology are increasingly recognized, with pulmonary vascular resistance identified as a therapeutic target to mitigate Fontan sequelae.
Do pulmonary vasodilators improve outcomes in patients with a failing Fontan circulation?
Do pulmonary vasodilators improve outcomes in patients with a failing Fontan circulation?
This review discusses the rationale and efficacy of pulmonary vasodilator therapy as a treatment strategy to mitigate sequelae in patients with a failing Fontan circulation.
Pulmonary vasodilators may mitigate sequelae in failing Fontan; leaves open confirmation of efficacy in prospective trials.
The Fontan operation is the final step of palliation for patients with a functionally single ventricle. Since its introduction in the 1970s, the Fontan surgery has become part of a successful surgical strategy that has improved single ventricle mortality. In recent years, we have become more aware of the limitations and long-term consequences of the Fontan physiology. Pulmonary vascular resistance plays an important role in total cavopulmonary circulation, and has been identified as a potential therapeutic target to mitigate Fontan sequelae. In this review, we will discuss the results of different pulmonary vasodilator trials and the use of pulmonary vasodilators as a treatment strategy for Fontan patients.
No takes yet. Share an insight, caveat, or question.
Snarr et al. (2015) conducted a review in Failing Fontan circulation. Pulmonary vasodilator therapy was evaluated. This review discusses the rationale and efficacy of pulmonary vasodilator therapy as a treatment strategy to mitigate long-term sequelae in patients with a failing Fontan circulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: